Addressing more generally the use of treatments directed at the pathogenesis of AD and AD-DS, and in view of increased APP gene dose in DS as well as changes in the processing of APP with absolute or relative increases in Aβ42 in the brain in all forms of AD, a focus on reducing the levels of APP and its products is rational. This evidence concerns the gene APP and Alzheimer disease.